16 Results for "

somatostatin secretion

" in MedChemExpress (MCE) Product Catalog:
Products (16)

16 Results for "somatostatin secretion" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-16381
CAS No.: 396091-73-9
Synonyms: SOM230
Target:  

Somatostatin Receptor

Research Areas:  

Endocrinology Cancer

Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16381A
CAS No.: 396091-76-2
Synonyms: SOM230 acetate
Target:  

Somatostatin Receptor

Research Areas:  

Endocrinology Cancer

Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1206
CAS No.: 174688-78-9
Target:  

Somatostatin Receptor

Research Areas:  

Neurological Disease

CH 275 is a peptidic somatostatin analog that acts as an agonist of SST1 (IC50 = 30.9 nM, Ki = 52 nM). The IC50 values of CH 275 for sst3, sst4, sst2, and sst5 are 345 nM, >1 μM, >10 μM, and >10 μM, respectively. CH 275 binds to SSTR1 via the IAmp9-Asp137 ion pair interaction and the hydrophobic interaction between the isopropyl group of IAmp9 and Leu107, and reduces the extracellular acidification rate. CH 275 induces weak sst1 internalization, exerts immunosuppressive effects on macrophages, and decreases macrophage viability, MCP-1 expression/secretion, and IL-8 secretion, but does not alter proMMP-9 secretion or IL-8 mRNA levels. CH 275 reduces hippocampal β-amyloid levels and alleviates plaque pathology without inducing hippocampal microglial activation. CH 275 is used in research on Alzheimer's disease, Parkinson's disease, and depression .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1547
CAS No.: 76461-17-1
Target:  

GHSR

Research Areas:  

Neurological Disease

Somatostatin-25 is a endogenous neuropeptide hormone that shows inhibitory activity against secretion of growth hormone.
loading...
    loading...
Cat. No.: HY-P3954
CAS No.: 73032-94-7
Target:  

Somatostatin Receptor

Research Areas:  

Metabolic Disease

Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .
loading...
    loading...
Cat. No.: HY-P3579
CAS No.: 11063-17-5
Synonyms: GIP (1-42), porcine
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Gastric Inhibitory Peptide (GIP (1-42)), porcine is a porcine glucose-dependent insulinotropic polypeptide and inhibitor of pentagastrin-stimulated gastric acid secretion. Gastric Inhibitory Peptide, porcine stimulates endogenous somatostatin release. Gastric Inhibitory Peptide, porcine acts in a dose- and time-dependent manner in conscious, chronic gastric fistula-equipped rats .
loading...
    loading...
Cat. No.: HY-106103
CAS No.: 81377-02-8
Purity:  99.30%
Synonyms: MK-678; L-363586
Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with pA2 values of 6.50, 6.24 and 6.09 against SS14, SS25 and SS28, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus .
loading...
    loading...
Cat. No.: HY-P3019
CAS No.: 357952-09-1
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF2β (Ki = 13.5 nM) and rCRF2α (Ki = 21.7 nM), while demonstrating negligible affinity for hCRF1 (Ki >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion [1][2].
loading...
    loading...
Cat. No.: HY-P0024A
CAS No.: 2126831-23-8
Synonyms: DG3173 TFA; PTR-3173 TFA
Target:  

Somatostatin Receptor

Research Areas:  

Endocrinology Cancer

Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent
loading...
    loading...
Cat. No.: HY-P3019A
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF2β (Ki = 13.5 nM) and rCRF2α (Ki = 21.7 nM), while demonstrating negligible affinity for hCRF1 (Ki >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .
loading...
    loading...
Cat. No.: HY-P0024
CAS No.: 252845-37-7
Synonyms: DG3173; PTR-3173
Target:  

Somatostatin Receptor

Research Areas:  

Endocrinology Cancer

Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared withOctreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent
loading...
    loading...
Cat. No.: HY-164040
CAS No.: 2604416-66-0
Target:  

Somatostatin Receptor

Research Areas:  

Metabolic Disease

Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC50 <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .
loading...
    loading...
Cat. No.: HY-110161
CAS No.: 1021912-42-4
sst2 Receptor agonist-1 is a potent somatostatin receptor subtype 2 (sst2) agonist with a Ki value of 0.025 nM and a cAMP IC50 value of 4.8 nM. sst2 Receptor agonist-1 can inhibit rat growth hormone (GH) secretion and ocular neovascular lesion formation. Antiangiogenic effect .
loading...
    loading...
Cat. No.: HY-P0221B
Target:  

PACAP Receptor

Research Areas:  

Endocrinology

PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .
loading...
    loading...
Cat. No.: HY-175053
Synonyms: SOM230 (aspartate) TFA
Research Areas:  

Metabolic Disease

Pasireotide (aspartate) TFA, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide (aspartate) TFA can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide (aspartate) TFA also exhibits antisecretory, antiproliferative, and proapoptotic activity .
loading...
    loading...
Cat. No.: HY-P2167
CAS No.: 99685-66-2
Somatostatin RC-102 is an octapeptide analog of Somatostatin. Somatostatin RC-102 inhibits the release of growth hormone and insulin. Somatostatin RC-102 enhances the inhibition of cell migration by increasing the production or activity of LMIF, but exerts no effect on cell migration in the absence of exposure to cardiac antigens or phytohemagglutinin. Somatostatin RC-102 inhibits gastric acid secretion. Somatostatin RC-102 can be used in the research of heart diseases .
loading...
    loading...
  • 1